| Biogenannounced 20 Jul 2022 |
Report Phase 3 data for lecanemab due after leader left |
No record found30 Nov 2022 |
| Biogenannounced 20 Jul 2022 |
Submit joint U.S. regulatory filing for zuranolone due after leader left |
Met31 Dec 2022 |
| Biogenannounced 3 May 2022 |
Complete the rolling submission for lecanemab under the accelerated approval pathway |
Met30 Jun 2022 |
| Biogenannounced 3 May 2022 |
Report the Phase 2 readout for BIIB104 in cognitive impairment |
Late30 Jun 2022 |
| Biogenannounced 3 May 2022 |
Report the Phase 3 SKYLARK study readout for PPD |
Met30 Jun 2022 |
| Biogenannounced 3 May 2022 |
Report the Phase 3 Clarity AD confirmatory study readout for lecanemab due after leader left |
Met30 Nov 2022 |
| Biogenannounced 3 May 2022 |
Complete the rolling submission of the New Drug Application for MDD due after leader left |
Met31 Dec 2022 |
| Biogenannounced 3 May 2022 |
File the New Drug Application for PPD due after leader left |
Met31 Mar 2023 |
| Biogenannounced 3 May 2022 |
Submit for full FDA approval for lecanemab due after leader left |
Met31 Mar 2023 |
| Biogenannounced 3 Feb 2022 |
Complete 5 key data readouts and 3 regulatory filings due after leader left |
No record found31 Dec 2022 |
| Biogenannounced 20 Oct 2021 |
Submit filing for zuranolone for postpartum depression due after leader left |
Met30 Jun 2023 |
| Biogenannounced 22 Apr 2021 |
Close the commercialization and license agreement for BAT1806 |
Met30 Jun 2021 |
| Biogenannounced 22 Jul 2020 |
Enroll first patients in the RESPOND clinical study |
Met31 Mar 2021 |
| Biogenannounced 22 Apr 2020 |
Complete the U.S. regulatory filing for aducanumab |
Met30 Sep 2020 |
| Biogenannounced 30 Jan 2020 |
Deliver 11 mid- to late-stage clinical data readouts |
No record found31 Dec 2021 |
| Biogenannounced 22 Oct 2019 |
Deliver nine clinical data readouts |
No record found31 Dec 2020 |
| Biogenannounced 24 Apr 2019 |
Complete the acquisition of Nightstar Therapeutics |
Met30 Jun 2019 |
| Biogenannounced 24 Apr 2019 |
Close the transaction with FUJIFILM regarding the Hillerød, Denmark manufacturing facility |
Met31 Dec 2019 |
| Biogenannounced 24 Apr 2019 |
Provide clinical program readouts across MS, ALS, Parkinson’s, and other neurological disease programs |
No record found31 Dec 2020 |
| Biogenannounced 29 Jan 2019 |
Initiate a Phase 3 clinical trial for vixotrigine in trigeminal neuralgia |
Not met31 Dec 2019 |
| Biogenannounced 24 Jul 2018 |
Close the acquisition of additional shares of Samsung Bioepis |
Met31 Dec 2018 |
| Biogenannounced 24 Apr 2018 |
Close the collaboration agreement with Ionis Pharmaceuticals |
Met30 Jun 2018 |
| Biogenannounced 24 Apr 2018 |
Launch IMRALDI in Europe |
Met31 Oct 2018 |
| Biogenannounced 24 Oct 2017 |
Report data from the Phase 2b ACTION2 study |
Met31 Mar 2018 |
| Biogenannounced 24 Oct 2017 |
Initiate a Phase 2b study for BG00011 |
Met31 Dec 2018 |
| Biogenannounced 25 Apr 2017 |
Close the acquisition of the BMS-986168 license |
Met30 Jun 2017 |
| Biogenannounced 26 Jan 2017 |
Complete the separation of the hemophilia business into Bioverativ |
Met1 Feb 2017 |